Skip to main content

Effect of opioid-sparing analgesia with continuous ketorolac and patient-controlled fentanyl on postoperative nausea and vomiting in female patients undergoing sleeve gastrectomy: a randomized controlled trial

In brief

Ketorolac-fentanyl PCA raised 12-to-24-hour nausea-free rates to 91%

In a randomized trial of 92 women having sleeve gastrectomy, 91% receiving ketorolac plus patient-controlled fentanyl had no nausea or vomiting from 12 to 24 hours, versus 58% with fentanyl alone. They used less fentanyl and had similar pain scores, but nausea and vomiting did not differ in the recovery unit; the findings need testing beyond this small, all-female study.

Journal
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery (Q1)
Published
14 October 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Insun Park, Hyo-Seok Na, Young Hyun Koo, Bon-Wook Koo, Jung-Hee Ryu, Jin-Hee Kim, et al.
PMID
43045614
DOI
10.1016/j.soard.2026.10.006

Why clinicians should know about it

Abstract

BACKGROUND: Postoperative nausea and vomiting (PONV) is common after laparoscopic sleeve gastrectomy (LSG) and is driven largely by opioid use. A dual-channel patient-controlled analgesia (PCA) device delivers continuous ketorolac with patient-controlled fentanyl, but whether this opioid-sparing regimen reduces PONV after LSG is unknown. OBJECTIVES: To compare the efficacy, side effects, and quality of recovery with ketorolac-fentanyl PCA versus fentanyl-only PCA in female patients undergoing LSG. SETTING: University tertiary hospital, Republic of Korea. METHODS: In this prospective, double-blind randomized trial, 92 women with severe obesity were assigned to ketorolac-fentanyl or fentanyl-only PCA. The primary outcome was PONV during the postanesthesia care unit (PACU) stay and up to 24 h postoperatively. The secondary outcomes included pain, rescue analgesia, fentanyl consumption, and Quality of Recovery-15 Korean version (QoR-15K) scores. RESULTS: PONV severity differed in favor of ketorolac-fentanyl at 0-6 h (P = .024), 6-12 h (P = .008), and 12-24 h (P = .016) but not in the PACU (P = .134); the proportion free of PONV was 53.7% versus 26.2%, 83.3% versus 44.1%, and 91.4% versus 57.7%. This persisted after adjustment for smoking status. Fewer patients discontinued PCA in the ketorolac-fentanyl group (P = .008). Total fentanyl consumption was reduced (237.5 vs. 522.0 μg, P < .001) with similar pain scores. QoR-15K scores were higher (P = .004), and ketorolac-fentanyl PCA was independently associated with good or excellent recovery (odds ratio [OR] 2.70, P = .049). CONCLUSIONS: Ketorolac-fentanyl PCA reduced PONV and opioid consumption and improved early recovery quality without compromising analgesia in women with severe obesity undergoing LSG.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.